

Annual Review of Virology

Abortive Infection: Bacterial Suicide as an Antiviral Immune Strategy

Anna Lopatina, Nitzan Tal, and Rotem Sorek

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel;
email: rotem.sorek@weizmann.ac.il

Annu. Rev. Virol. 2020. 7:371–84

First published as a Review in Advance on
June 19, 2020

The *Annual Review of Virology* is online at
virology.annualreviews.org

<https://doi.org/10.1146/annurev-virology-011620-040628>

Copyright © 2020 by Annual Reviews.
All rights reserved

**ANNUAL
REVIEWS CONNECT**

www.annualreviews.org

- Download figures
- Navigate cited references
- Keyword search
- Explore related articles
- Share via email or social media

Keywords

bacterial defense, abortive infection, toxin-antitoxin, CRISPR-Cas, CBASS, phage resistance

Abstract

Facing frequent phage challenges, bacteria have evolved numerous mechanisms to resist phage infection. A commonly used phage resistance strategy is abortive infection (Abi), in which the infected cell commits suicide before the phage can complete its replication cycle. Abi prevents the phage epidemic from spreading to nearby cells, thus protecting the bacterial colony. The Abi strategy is manifested by a plethora of mechanistically diverse defense systems that are abundant in bacterial genomes. In turn, phages have developed equally diverse mechanisms to overcome bacterial Abi. This review summarizes the current knowledge on bacterial defense via cell suicide. It describes the principles of Abi, details how these principles are implemented in a variety of natural defense systems, and discusses phage counter-defense mechanisms.

INTRODUCTION

Bacteria encode multiple lines of defense against viruses that infect them, termed phages. These include defense systems with well-understood mechanisms of action, such as restriction-modification and CRISPR-Cas systems, as well as many recently discovered systems with unknown modes of action (for recent reviews, see 1–3). In general, bacteria are known to resist phage infections by mutating or altering their surface receptors (4), targeting the phage nucleic acids (3), producing small molecules that poison phage replication (5), or committing suicide upon phage infection. The latter mode of protection, termed abortive infection (Abi), is the topic of this review.

The term abortive infection in the context of nonproductive phage replication had appeared in the literature already in the 1950s. However, only in the 1980s did the term become widely adopted to describe a mode of bacterial defense in which the infection process is inhibited at a relatively late stage of the infection cycle and the bacterial cells are killed in the process (6). Over the years, many bacterial defense systems that have been discovered were tagged as Abi systems; however, in many cases (especially in systems detected in *Lactococci*), cell suicide or growth arrest was not explicitly demonstrated. In this review, we primarily describe defense by Abi in the strict sense, meaning that we mainly discuss defense systems in which cell suicide or growth impairment clearly plays a major role in the mechanism of defense. In some cases, Abi systems are known to have bacteriostatic effects (inflicting metabolic arrest) rather than bactericidal effects (killing the cell); we also describe such systems in this review because the lines between metabolic arrest and cell death are sometimes blurry and because prolonged bacteriostasis can eventually result in cell death (7).

OPERATIONAL PRINCIPLES OF ABORTIVE INFECTION

Abi is not a defense system per se; rather, it is an immune strategy that is manifested in many different kinds of defense systems encoded by bacteria. The core principle of this strategy is that a bacterial cell, after sensing the infection, commits suicide before the phage can complete its replication cycle. This ensures that no mature phage particles emerge from the infected cell, so that the phage epidemic cannot spread to infect nearby cells and the colony ultimately survives (**Figure 1**). Abi can be regarded as an altruistic trait, as one cell sacrifices itself to benefit the community. However, considering that bacteria frequently live in colonies of isogenic or almost isogenic cells, and because phages are often highly specific and infect just one species or subspecies of bacteria, this altruism is expected to primarily protect only very closely related kin (8–10).

Because defense systems such as CRISPR-Cas and restriction-modification can mitigate phage infection without killing the infected cells, Abi makes biological sense mainly when the first lines of defense have failed and chances of survival of the infected cell are already low. Therefore, whereas restriction enzymes target the phage DNA at very early stages of the infection, Abi systems are usually expected to become activated only when the phage reaches the middle or late stages of its infection cycle (3, 6, 11). In this scenario, Abi systems will not lead to cell death if the cell overcame the infection by other means at some earlier stages; however, if the first lines of defense have failed and the phage proceeded into advanced stages of its replication cycle, Abi is activated as a defense of last resort.

Every Abi system must contain at least two functional modules: one that senses the phage infection and one that kills the cell or shuts down metabolism once the phage has been sensed. Abi systems can sense intermediates of phage genome replication (12), structural phage proteins that are sensed during their production within the cell (13, 14), or other phage proteins expressed in the cell during infection (15, 16). Abi systems can also sense extensive transcription from phage DNA (17, 18) or phage-mediated shutoff of host gene expression (19); in some cases, an Abi system is activated only when it senses that a phage has inhibited another, non-Abi defense system (12).




Figure 1

Key principles of the Abi strategy. (a) Infection of a culture that does not encode an Abi system. (b) Infection of a culture that encodes an Abi system. Abbreviation: Abi, abortive infection.

Once phage infection has been sensed, the cell-killing module becomes activated. This module must be tightly suppressed before infection so that it does not impair bacterial growth under normal conditions (1). When activated, the module must function relatively rapidly, as it must cause cell death or metabolic arrest before new phage particles mature in the infected cell. Abi systems can lead to cell death by degrading (20) or depolarizing (16, 21, 22) the inner membrane or by indiscriminately degrading phage and host DNA (23). Other Abi systems, when activated, degrade transfer RNAs (tRNAs) (24), cleave essential proteins in the host translation machinery (25), or indiscriminately degrade phage and host messenger RNAs (mRNAs) (17, 18, 26, 27). In these cases, the host cell enters an immediate growth arrest that can result in eventual cell death but is sometimes reversible (28). It has also been suggested that temporary growth arrest can buy time for other defense systems, such as restriction enzymes and CRISPR-Cas, to inactivate the phage (1, 29).

The following sections describe individual examples of Abi systems in which at least one of the modules (phage sensing or cell killing) is understood. We describe classical Abi systems that were discovered decades ago and expand on recently discovered systems, including cyclic oligonucleotide-based antiphage signaling system (CBASS) and type III CRISPR-Cas systems, that use small-molecule signaling as a way to transmit the information between the phage-sensing and cell-killing modules. We also describe a variety of mechanisms by which phages can evade bacterial Abi systems.

DIVERSITY OF ABORTIVE INFECTION SYSTEMS IN BACTERIA

For many years, *Escherichia coli* has served as the most widely used model organism to study phage infection, and so most of the mechanistic understandings of Abi systems were achieved in *E. coli*

model systems (30). *Lactococcus lactis* has also been extensively studied for its capacity to restrict phage infections, and in fact, more than 20 different defense genes or systems were reported in that bacterium as Abi systems (designated AbiA to AbiZ) (11, 31–33). However, to our knowledge, for only a small minority of these (e.g., AbiZ, described in more detail below) is the mechanism of phage sensing and/or cell killing understood.

One of the first Abi systems to be deciphered in *E. coli* was Rex (3, 34). The Rex system is expressed from a repressed lambda prophage and comprises two genes, *rexA* and *rexB*, both of which are required for the defensive activity (35, 36). The system was shown to restrict plaque formation of several lambdoid phages, as well as particular strains of T4, T7, and T5 phages (37). The RexA protein is thought to sense a protein-DNA complex that may be produced as an intermediate of phage replication or recombination (12). Two copies of RexA then activate one copy of RexB, a membrane-anchored protein containing four transmembrane helices (21). When activated, RexB forms an ion channel in the inner membrane, resulting in a severe loss of membrane potential and a consequent drop in cellular ATP levels; this inhibits bacterial growth and aborts phage infection (**Figure 2a**). Some studies have suggested that RexB activation results in cell death (21), while other studies proposed that Rex toxicity induces a stationary phase-like state from which some cells can recover after viral infection is mitigated (28). As part of the arms race of bacterial defense and phage counterattacks, phages have evolved ways to overcome the Rex system. For example, the wild-type T4 phage encodes two proteins (RIIA and RIIB) that mitigate the activity of the Rex system via an unknown mechanism, and hence only mutant T4 strains in which the rII locus is inactivated are blocked by the Rex system (38).

The Abi gene *abiZ*, which protects *L. lactis* against the infection of phage phi31, also induces cell killing by damaging the cell membrane of the infected cell (16). This membrane-bound protein acts cooperatively with the lysin and holin proteins of the phage that are expressed late in the infection cycle and accelerates cell lysis (**Figure 2a**). Premature cell lysis causes the infected cells to burst and to release unassembled phage particles that are not capable of infecting further cells (16).

Another Abi system that was described in *E. coli* is PifA, which aborts the infection of phage T7 midway through its infection cycle. While the initial steps of T7 infection occur normally, late gene transcription is severely reduced and phage DNA replication is abolished. Activation of PifA leads to leakage of ATP through loss of membrane integrity, and, although the infected cells do not lyse, they die (22). The *pifA* gene, encoded on the F plasmid, is responsible for the Abi phenotype (39). This gene is coexpressed on the same operon with *pifC*, a transcriptional repressor that inhibits its own expression as well as the expression of *pifA* (40), a concept that was later referred to as type IV toxin-antitoxin (TA) and is also manifested by the Abi system AbiE (41). The PifA protein was found to be associated with the membrane, although no transmembrane helices can be detected in the protein sequence, and it contains an ATP/GTP binding domain essential for its defensive activity (39). The T7 capsid protein gp10 is the trigger for activation of PifA toxicity (13), but the exact mode by which PifA senses this protein is unknown. Another T7 protein that induces the toxicity of PifA is gp1.2, an inhibitor of deoxynucleotide hydrolysis in the infected cell (13). Accordingly, T7 phages carrying mutations in both *gp1.2* and *gp10* genes escape the PifA-mediated defense (42).

Several Abi systems, including Lit and PrrC, have been shown to induce cell death by inactivating the host translation machinery. Lit is a protease that is encoded by the defective e14 prophage of *E. coli* K12 (43). Its name, an acronym for Late Inhibition of T4, stems from its original identification as a protein that inhibits T4 late gene expression (44). The Lit protease is activated when gp23, the major head protein of phage T4, is expressed in the cell (25). This phage head protein binds the translation elongation factor EF-Tu, and this complex is identified by Lit (14). Once activated, Lit cleaves EF-Tu between Gly⁵⁹ and Ile⁶⁰ in the conserved nucleotide-binding




Figure 2

Mechanisms of action of a selected set of phage abortive infection systems. (a) The RexAB and AbiZ systems target bacterial cell membranes. RexA senses a phage protein-DNA complex formed as an intermediate of phage replication and activates RexB, which forms the ion channel in the membrane. AbiZ recognizes the holins and lysins of the phage and cooperatively acts with them to induce premature cell lysis. (b) PrrC is a protein that monitors the normal activity of the type I restriction enzyme *EcoprrI*. PrrC in its latent form binds to the *EcoprrI* protein complex. The T4 phage protein Stp binds *EcoprrI* and inhibits it, leading to the activation of PrrC. Activated PrrC cleaves tRNA^{lys}, causing protein synthesis to halt and phage infection to be terminated. (c) The Stk2 kinase is activated by the Pack phage protein. Activated Stk2 kinase phosphorylates multiple cell proteins, eventually leading to cell death and termination of phage infection. (d) RnlAB is a type II toxin-antitoxin system consisting of the endoribonuclease toxin RnlA and its cognate antitoxin RnlB. During T4 phage infection, the host protein synthesis is shut off, and because the antitoxin is unstable, it gets rapidly degraded. This releases the RnlA toxin, which indiscriminately cleaves host and phage RNA. Abbreviation: tRNA^{lys}, transfer RNA lysine.

domain of EF-Tu (45), thus inhibiting cellular protein translation and arresting bacterial growth (14). Mutations in T4 gp23 that resulted in escape from Lit localized the domain identified by Lit to a short sequence (29 amino acids) denoted Gol for Grow On Lit-producing bacteria (46) that is highly conserved in head proteins of T-even phages (47).

prrC is a unique Abi gene that is activated as a secondary line of defense only when the first defensive lines have collapsed (Figure 2b). The *prrC* gene was found to be encoded by the clinical *E. coli* strain CT196 (48, 49). Under normal conditions, PrrC binds the type I restriction endonuclease *EcoprrI* and does not interfere with its endonuclease activity (24, 50). Rather, PrrC monitors the normal activity of the restriction enzyme and becomes activated only when the restriction enzyme is tampered with. Specifically, phage T4 encodes a short peptide called Stp, which binds and inhibits the *EcoprrI* restriction enzyme (51). Inhibition of *EcoprrI* by Stp activates a ribonuclease domain in PrrC, and activated PrrC then cleaves tRNA^{lys}, causing protein synthesis to halt (52). The T4 phage encodes a mechanism that enables the religation of tRNA^{lys}, and it is thought that this mechanism (manifested by two enzymes: polynucleotide kinase and RNA ligase) has evolved

to overcome PrrC defense (53). Therefore, PrrC defends, through Abi, against only T4 phages in which either the polynucleotide kinase or the RNA ligase have been inactivated (54).

A recently discovered Abi gene was shown to protect species of *Staphylococcus* against *Siphoviridae* phages via phosphorylation of cellular proteins (15). The kinase gene, *Stk2*, is activated by a phage protein called PacK, which was hypothesized to play a role in phage DNA packaging (Figure 2c). Once activated, *Stk2* phosphorylates multiple proteins in the cell, eventually leading to cell death (15).

TOXIN-ANTITOXIN SYSTEMS AND ABORTIVE INFECTION

A TA system comprises a pair of genes, usually transcribed from the same operon; the first is toxic, and the second confers immunity to this toxicity (55). TA systems have been divided into six types according to the nature of the toxin and antitoxin molecules and the mode of immunity regulation. The most common type is type II TA systems, where both the toxin and the antitoxin are proteins, and the antitoxin physically binds to the toxin and prevents its toxic activity (56). According to the paradigm of type II TA systems' mode of action, the antitoxin is less stable than the toxin and is more prone to be degraded by cellular proteases. When the cell enters conditions of stress and protein production halts, the antitoxin is rapidly degraded and the stable toxin is no longer suppressed (57).

Type II TA systems are extremely abundant in microbial genomes, with some genomes encoding more than 80 such systems (58). They have been shown to play roles in bacterial responses to various stress conditions (59), confer resistance to antibiotics via persistence (60), and take part in biofilm formation regulation (61) and plasmid maintenance (62). TA systems have also been proposed to play a role in phage defense via Abi (1, 3), but evidence for this role is limited to a very few well-established examples, and a general role for TA systems in phage defense is still under dispute (63).

RnlAB (also called RNase LS) is a type II TA system encoded by *E. coli* K12 that protects against certain strains of phage T4 via Abi (19) (Figure 2d). RnlA is an endoribonuclease toxin that is inhibited by direct interaction with its cognate antitoxin, RnlB. While the half-life of the RnlA toxin is more than 25 min, the half-life of RnlB is much shorter, estimated to be ~2 min due to rapid proteolysis by *E. coli* housekeeping proteases (19). Because T4 infection rapidly shuts off host gene expression (64), the unstable antitoxin RnlB gets degraded soon upon phage infection, releasing RnlA to become an active endoribonuclease that indiscriminately degrades phage and host mRNAs, presumably leading to cell death (26, 65). A homologous system called LsoAB encoded on a plasmid of *E. coli* strain O157:H7 shows similar antiphage functionality (26). Interestingly, the wild-type T4 phage encodes a gene called *dmd* that can overcome defense by RnlAB. This gene is expressed early in infection and encodes an antitoxin mimic that binds and neutralizes the RnlA toxin (26). In accordance with this, RnlAB provides resistance against only T4 phage strains that are mutated in *dmd*.

Another example of TA-mediated Abi is the ToxIN system, which was shown to provide phage resistance in various enteric bacteria, including *Erwinia carotovora*, *Serratia marcescens*, and *E. coli* (27). ToxIN [originally identified as AbiQ of *L. lactis* (66)] is a type III TA system where the antitoxin (ToxI) is a noncoding RNA that physically binds the ToxN toxin protein and inhibits its activity (67). In uninfected cells ToxI and ToxN are found as an inactive RNA:protein complex comprising three ToxI RNAs and three ToxN proteins (67). ToxN is an endoribonuclease, and upon phage infection it becomes activated and presumably cleaves cellular and phage RNA, stopping phage production and causing bacteriostasis or cell death (27). Homologs of *toxN* are found in the genomes of a wide range of Gram-positive and Gram-negative bacteria, with most of the

toxN-encoding loci located on plasmids, suggesting that these defense systems spread in bacteria via extensive horizontal gene transfer (27). Interestingly, some phages escape ToxIN by expressing a noncoding RNA that mimics the ToxI antitoxin and inhibits ToxN toxicity (68).

CYCLIC OLIGONUCLEOTIDE-BASED ANTIPHAGE SIGNALING SYSTEMS

Recently, a large new family of Abi systems, collectively called CBASS, has been described (20). In these systems, the phage-sensing module is disconnected from the cell-killing module and the proteins that encode these two functions do not physically interact. Rather, when the phage-sensing protein identifies phage infection, it produces a small secondary messenger molecule comprising two or three nucleotides covalently linked to form a cyclic molecule (cyclic dinucleotide or cyclic trinucleotide), and this secondary messenger molecule activates the cell-killing effector protein that carries out the Abi (20) (Figure 3).

The most extensively studied CBASSs to date are two homologous systems encoded by *Vibrio cholerae* El Tor and *E. coli* TW11681. When cloned into a lab strain of *E. coli* that lacks CBASS, these systems protected against a wide variety of phages (20). The key components of the system are a protein called DncV that can produce cyclic GMP-AMP (cGAMP) molecules (69), and CapV, which is a phospholipase activated by cGAMP (70). The cGAMP-producing DncV protein is inactive in uninfected cells, but infection by phage triggers the production of cGAMP that




Figure 3

The CBASS abortive infection system. The system is composed of an oligonucleotide cyclase and an effector gene. The oligonucleotide cyclase (in this figure, cGAS) is activated during phage infection by an unknown phage component. Production of the cyclic oligonucleotide activates a cell-killing effector protein, which (depending on the CBASS type) can be a phospholipase, a nuclease, or a membrane-spanning protein. Abbreviations: CBASS, cyclic oligonucleotide-based antiphage signaling system; cGAS, cyclic GMP-AMP synthase.

accumulates to micromolar-level concentrations in the cell. The cGAMP then binds and activates the cognate phospholipase protein, which degrades the inner membrane, leading to cell lysis and death (20).

The activity of CBASS was shown to be temporally coordinated so that, on one hand, cell death occurs before the phage can generate mature particles, and, on the other hand, the cell commits to death only after the phage has advanced to late stages in its replicative cycle. When infected by phage P1, cells encoding the *E. coli* TW11681-derived CBASS began generating the secondary messenger cGAMP 30–40 min after the initial infection, and culture lysis due to CapV phospholipase activity was observed a few minutes after that (20). Considering that P1-infected CBASS-lacking cultures lyse after 60–70 min due to phage-induced lysis, the CBASS system seems to become active only when the phage has temporally completed about half of its replicative cycle. It was shown that cell lysis by CBASS does not release mature infective particles because a CBASS-encoding culture in which only 20% of bacteria were initially infected does not undergo collapse (20). The phage component sensed by the *E. coli* TW11681 CBASS is currently unknown.

The bacterial CBASS shows structural and functional homology with the cGAS-STING antiviral pathway of animal cells. CBASSs were identified in more than 10% of sequenced bacterial and archaeal genomes and span a remarkable diversity of oligonucleotide cyclase and effector protein activities (20, 71). Oligonucleotide cyclase proteins in different CBASSs can produce a variety of cyclic oligonucleotide signals in addition to cGAMP, including cyclic AMP-UMP, cyclic UMP-UMP, cyclic AMP-AMP-GMP, and others (71). The cell-killing domain in the effector gene also varies, with effectors including, in addition to phospholipases, endonucleases that can indiscriminately degrade DNA (23, 72), transmembrane domains that are thought to form membrane-spanning ion channels (20, 73), and other domains whose mechanisms of cell killing are unknown. In many cases CBASS operons contain, in addition to the two core genes, ancillary genes of unknown function that were shown to be necessary for protection against some (but not all) of the phages (20).

The abundance and diversity of CBASS in microbes suggest that transferring the information on phage sensing via a secondary messenger mediator is a successful strategy. The enzymatic activity of the oligonucleotide cyclase rapidly amplifies the signal when the phage is sensed, so that in principle a single sensor can activate multiple cell-killing effectors. Presumably, this accelerates the process and shortens the time that elapses from phage sensing to the execution of cell killing, reducing the chances that the phage would complete its replication during that time.

ABORTIVE INFECTION IN CRISPR-ASSOCIATED DEFENSE

CRISPR-Cas is the adaptive immune system of bacteria and archaea, capable of acquiring short pieces of phage DNA and storing them as spacers between repetitive sequences to form an immune memory (74–76). These spacers are subsequently expressed and processed into short CRISPR RNAs (crRNAs) that become complexed with Cas proteins, forming a complex that searches for and destroys phage nucleic acids that base pair with the crRNA (74–76).

Type I CRISPR-Cas systems, which are the most abundant CRISPR-Cas systems in nature (77), and type II systems, which include Cas9, both degrade phage DNA and are capable of abolishing the infection without necessitating cell death. However, recent findings show that type III CRISPR-Cas systems can sometimes lead to Abi (17, 18). In these systems, the crRNA-Cas complex binds to phage RNA rather than DNA. The phage RNA is recognized during active transcription from the phage genome (78) and then cleaved by the Csm3 (in CRISPR-Cas type IIIA) or Cmr4 (type IIIB) subunit of the crRNA/protein complex. At the same time, another component of the complex (Cas10) cleaves the DNA from which the RNA was transcribed




Figure 4

The mechanism of abortive infection by type III CRISPR-Cas systems. The crRNA-Cas complex binds to phage RNA during its active transcription from phage DNA. The crRNA-Cas complex cleaves both the phage RNA and the DNA from which it was transcribed. At the same time, it produces cOA molecules. The cOA molecules bind and activate the nonspecific RNase Csm6, which subsequently indiscriminately degrades phage and host RNA. Abbreviations: cOA, cyclic oligoadenylate; crRNA, CRISPR RNA; RNAP, RNA polymerase.

(79, 80). It was recently shown that recognition and cleavage of phage RNA induces a third enzymatic activity by the Palm domain of Cas10 (17, 18). Once the phage RNA is identified by base pairing with the crRNA, Cas10 synthesizes a cyclic oligoadenylate (cOA) small-molecule secondary messenger comprising four or six adenosine monophosphate (AMP) molecules covalently bound to each other in a cyclic configuration (17, 18) (**Figure 4**). The cOA molecules then bind and activate an effector RNase called Csm6 that indiscriminately degrades both phage and host RNAs, presumably leading to cell dormancy and sometimes death (17, 18).

There is a clear biological rationale in the mode of defense employed by type III CRISPR-Cas systems. These systems become activated only if the first lines of defense (for example, type I or type II CRISPR-Cas or restriction enzymes) have failed to inactivate the phage by degrading its DNA because transcription from the phage DNA is a signature for active propagation of the phage infection process. When phage transcription is recognized, the type III CRISPR-Cas system attempts to inactivate it by cleaving both the transcribed RNA and the phage DNA. During that time, it produces a limited amount of the cOA signal. Presumably, a limited amount of cOA molecules produced by a single recognition event will not be sufficient to induce full-fledged toxicity by Csm6, but if multiple phage loci are identified by the type III CRISPR-Cas system, it would mean that the phage genome has already managed to replicate and phage gene expression is abundant. In this case, the chances that the cell would eventually survive are poor, and accumulation of a high concentration of cOA in the cell will maximally activate Csm6, presumably leading to cell death (81). Interestingly, recent findings show that bacteria encode enzymes that can hydrolyze cOA molecules; these enzymes can clear the cell from residual cOAs in case it was able to survive the phage infection and resuscitate it from Csm6-induced dormancy (82, 83).

Abi was also suggested to be the outcome of type VI CRISPR-Cas systems (84). The effector protein in these systems is Cas13, which uses crRNAs to locate phage RNA. Base pairing with

phage RNA results in cleavage of the RNA but also induces a nonspecific RNase activity of Cas13 that cleaves both cell and phage mRNAs, resulting in dormancy (84, 85).

SUMMARY AND OUTLOOK

This article reviewed Abi systems that have been discovered and studied over a period of more than four decades. As multiple excellent reviews have covered early discoveries on Abi systems in depth (3, 32, 86), we naturally expanded the discussion on the newer discoveries from the past few years. As indicated above, we did not enumerate all known defense systems that have been described as Abi systems but rather focused on in-depth description of systems that comply with the strict definition, i.e., in which cell death or dormancy was clearly attributed to the activity of the defense system. We also attempted to focus on Abi systems in which at least part of the mechanism has been elucidated.

While the mechanistic diversity of Abi systems has been recognized for several decades, their abundance in nature was not fully appreciated. The recent discovery of CBASS and type III CRISPR-Cas systems as widespread and abundant Abi systems suggests that cell suicide is an immunological strategy that may be much more abundant in bacteria and archaea than previously realized. Historically, Abi was studied mainly in *E. coli* and *Lactococci*. With the huge expansion of genomic information available today, studies focusing on defense systems in nonmodel organisms are likely to reveal many additional systems that rely on suicide of the infected cell for the benefit of colony survival. Indeed, multiple new antiphage systems found to be encoded by prophages in *Mycobacterium* and *Gordonia* were suggested to function via Abi (87–89). Future studies on these systems, as well as on other defense systems encoded in bacteria, may result in an additional wave of discoveries that would expand the already fascinating diversity of known Abi mechanisms.

DISCLOSURE STATEMENT

R.S. is a scientific cofounder and consultant of BiomX, Pantheon Bioscience, and Ecophage.

ACKNOWLEDGMENTS

We thank the Sorek laboratory members for comments on earlier versions of this manuscript. R.S. was supported, in part, by the Israel Science Foundation (personal grant 1360/16), the European Research Council (grant ERC-CoG 681203), the German Research Council priority program SPP 2002 (grant SO 1611/1-1), the Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine, and the Knell Family Center for Microbiology. A.L. was supported, in part, by the Koshland Foundation.

LITERATURE CITED

1. Rostøl JT, Marraffini L. 2019. (Ph)ighting phages: how bacteria resist their parasites. *Cell Host Microbe* 25:184–94
2. Bernheim A, Sorek R. 2020. The pan-immune system of bacteria: antiviral defence as a community resource. *Nat. Rev. Microbiol.* 18:113–19
3. Dy RL, Richter C, Salmond GPC, Fineran PC. 2014. Remarkable mechanisms in microbes to resist phage infections. *Annu. Rev. Virol.* 1:307–31
4. Clément JM, Lepouce E, Marchal C, Hofnung M. 1983. Genetic study of a membrane protein: DNA sequence alterations due to 17 lamB point mutations affecting adsorption of phage lambda. *EMBO J.* 2(1):77–80

5. Kronheim S, Daniel-Ivad M, Duan Z, Hwang S, Wong AI, et al. 2018. A chemical defence against phage infection. *Nature* 564(7735):283–86
6. Duckworth DH, Glenn J, McCorquodale DJ. 1981. Inhibition of bacteriophage replication by extrachromosomal genetic elements. *Microbiol. Rev.* 45(1):52–71
7. Peeters SH, de Jonge MI. 2018. For the greater good: programmed cell death in bacterial communities. *Microbiol. Res.* 207:161–69
8. Hamilton WD. 1964. The genetical evolution of social behaviour. I. *J. Theor. Biol.* 7(1):1–16
9. Van Houte S, Buckling A, Westra ER. 2016. Evolutionary ecology of prokaryotic immune mechanisms. *Microbiol. Mol. Biol. Rev.* 80(3):745–63
10. Fukuyo M, Sasaki A, Kobayashi I. 2012. Success of a suicidal defense strategy against infection in a structured habitat. *Sci. Rep.* 2:238
11. Forde A, Fitzgerald GF. 1999. Bacteriophage defence systems in lactic acid bacteria. *Antonie Van Leeuwenboek* 76(1–4):89–113
12. Snyder L. 1995. Phage-exclusion enzymes: a bonanza of biochemical and cell biology reagents? *Mol. Microbiol.* 15(3):415–20
13. Schmitt CK, Molineux IJ. 1991. Expression of gene *1.2* and gene *10* of bacteriophage T7 is lethal to F plasmid-containing *Escherichia coli*. *J. Bacteriol.* 173(4):1536–43
14. Bingham R, Ekunwe SI, Falk S, Snyder L, Kleanthous C. 2000. The major head protein of bacteriophage T4 binds specifically to elongation factor Tu. *J. Biol. Chem.* 275(30):23219–26
15. Depardieu F, Didier J-P, Bernheim A, Sherlock A, Molina H, et al. 2016. A eukaryotic-like serine/threonine kinase protects Staphylococci against phages. *Cell Host Microbe* 20(4):471–81
16. Durmaz E, Klaenhammer TR. 2007. Abortive phage resistance mechanism *AbiZ* speeds the lysis clock to cause premature lysis of phage-infected *Lactococcus lactis*. *J. Bacteriol.* 189(4):1417–25
17. Kazlauskienė M, Kostiuik G, Venclovas Č, Tamulaitis G, Siksnys V. 2017. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. *Science* 357(6351):605–9
18. Niewoehner O, Garcia-Doval C, Rostøl JT, Berk C, Schwede F, et al. 2017. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers. *Nature* 548(7669):543–48
19. Koga M, Otsuka Y, Lemire S, Yonesaki T. 2011. *Escherichia coli rnlA* and *rnlB* compose a novel toxin-antitoxin system. *Genetics* 187(1):123–30
20. Cohen D, Melamed S, Millman A, Shulman G, Oppenheimer-Shaanan Y, et al. 2019. Cyclic GMP-AMP signalling protects bacteria against viral infection. *Nature* 574(7780):691–95
21. Parma DH, Snyder M, Sobolevski S, Nawroz M, Brody E, Gold L. 1992. The Rex system of bacteriophage lambda: tolerance and altruistic cell death. *Genes Dev.* 6(3):497–510
22. Schmitt CK, Kemp P, Molineux IJ. 1991. Genes *1.2* and *10* of bacteriophages T3 and T7 determine the permeability lesions observed in infected cells of *Escherichia coli* expressing the F plasmid gene *pifA*. *J. Bacteriol.* 173(20):6507–14
23. Lau RK, Ye Q, Birkholz EA, Berg KR, Patel L, et al. 2020. Structure and mechanism of a cyclic trinucleotide-activated bacterial endonuclease mediating bacteriophage immunity. *Mol. Cell* 77(4):723–33
24. Levitz R, Chapman D, Amitsur M, Green R, Snyder L, Kaufmann G. 1990. The optional *E. coli prr* locus encodes a latent form of phage T4-induced anticodon nuclease. *EMBO J.* 9(5):1383–89
25. Yu YT, Snyder L. 1994. Translation elongation factor Tu cleaved by a phage-exclusion system. *PNAS* 91(2):802–6
26. Otsuka Y, Yonesaki T. 2012. Dmd of bacteriophage T4 functions as an antitoxin against *Escherichia coli* LsoA and RnlA toxins. *Mol. Microbiol.* 83(4):669–81
27. Fineran PC, Blower TR, Foulds IJ, Humphreys DP, Lilley KS, Salmond GPC. 2009. The phage abortive infection system, ToxIN, functions as a protein-RNA toxin-antitoxin pair. *PNAS* 106(3):894–99
28. Slavcev RA, Hayes S. 2003. Stationary phase-like properties of the bacteriophage λ Rex exclusion phenotype. *Mol. Genet. Genom.* 269(1):40–48
29. Makarova KS, Anantharaman V, Aravind L, Koonin EV. 2012. Live virus-free or die: coupling of antiviral immunity and programmed suicide or dormancy in prokaryotes. *Biol. Direct* 7:40

30. Keen EC. 2015. A century of phage research: bacteriophages and the shaping of modern biology. *Bioessays* 37(1):6–9
31. Sing WD, Klaenhammer TR. 1990. Plasmid-induced abortive infection in lactococci: a review. *J. Dairy Sci.* 73(9):2239–51
32. Chopin M-C, Chopin A, Bidnenko E. 2005. Phage abortive infection in lactococci: variations on a theme. *Curr. Opin. Microbiol.* 8(4):473–79
33. Barrangou R, Horvath P. 2011. Lactic acid bacteria defenses against phages. In *Stress Responses of Lactic Acid Bacteria*, ed. E Tsakalidou, K Papadimitriou, pp. 459–78. Boston, MA: Springer US
34. Benzer S. 1955. Fine structure of a genetic region in bacteriophage. *PNAS* 41(6):344–54
35. Landsmann J, Kroger M, Hobom G. 1982. The *rex* region of bacteriophage lambda: two genes under three-way control. *Gene* 20(1):11–24
36. Snyder L, McWilliams K. 1989. The *rex* genes of bacteriophage lambda can inhibit cell function without phage superinfection. *Gene* 81(1):17–24
37. Toothman P, Herskowitz I. 1980. Rex-dependent exclusion of lambdaoid phages. II. Determinants of sensitivity to exclusion. *Virology* 102(1):147–60
38. Shinedling S, Parma D, Gold L. 1987. Wild-type bacteriophage T4 is restricted by the lambda *rex* genes. *J. Virol.* 61(12):3790–94
39. Cheng X, Wang W, Molineux IJ. 2004. F exclusion of bacteriophage T7 occurs at the cell membrane. *Virology* 326(2):340–52
40. Miller JF, Malamy MH. 1983. Identification of the *pifC* gene and its role in negative control of F factor *pif* gene expression. *J. Bacteriol.* 156(1):338–47
41. Dy RL, Przybicki R, Semeijn K, Salmond GPC, Fineran PC. 2014. A widespread bacteriophage abortive infection system functions through a Type IV toxin-antitoxin mechanism. *Nucleic Acids Res.* 42(7):4590–605
42. Molineux IJ, Schmitt CK, Condreay JP. 1989. Mutants of bacteriophage T7 that escape F restriction. *J. Mol. Biol.* 207(3):563–74
43. Kao C, Snyder L. 1988. The *lit* gene product which blocks bacteriophage T4 late gene expression is a membrane protein encoded by a cryptic DNA element, e14. *J. Bacteriol.* 170(5):2056–62
44. Cooley W, Sirotkin K, Green R, Snyder L. 1979. A new gene of *Escherichia coli* K-12 whose product participates in T4 bacteriophage late gene expression: interaction of *lit* with the T4-induced polynucleotide 5'-kinase 3'-phosphatase. *J. Bacteriol.* 140(1):83–91
45. Sprinzl M. 1995. Elongation factor Tu: a regulatory GTPase with an integrated effector. *Trends Biochem. Sci.* 19:245–50
46. Champness WC, Snyder L. 1982. The *gol* site: a *Cis*-acting bacteriophage T4 regulatory region that can affect expression of all the T4 late genes. *J. Mol. Biol.* 155(4):395–407
47. Monod C, Repoila F, Kutateladze M, Tétart F, Krisch H. 1997. The genome of the pseudo T-even bacteriophages, a diverse group that resembles T4. *J. Mol. Biol.* 267(2):237–49
48. Depew RE, Cozzarelli NR. 1974. Genetics and physiology of bacteriophage T4 3'-phosphatase: evidence for involvement of the enzyme in T4 DNA metabolism. *J. Virol.* 13(4):888–97
49. Kaufmann G, David M, Borasio GD, Teichmann A, Paz A, et al. 1986. Phage and host genetic determinants of the specific anticodon loop cleavages in bacteriophage T4-infected *Escherichia coli* CTx5X. *J. Mol. Biol.* 188(1):15–22
50. Tyndall C, Meister J, Bickle TA. 1994. The *Escherichia coli* *prf* region encodes a functional type IC DNA restriction system closely integrated with an anticodon nuclease gene. *J. Mol. Biol.* 237(3):266–74
51. Amitsur M, Morad I, Kaufmann G. 1989. *In vitro* reconstitution of anticodon nuclease from components encoded by phage T4 and *Escherichia coli* CTx5X. *EMBO J.* 8(8):2411–15
52. Amitsur M, Morad I, Chapman-Shimshoni D, Kaufmann G. 1992. HSD restriction-modification proteins partake in latent anticodon nuclease. *EMBO J.* 11(8):3129–34
53. Amitsur M, Levitz R, Kaufmann G. 1987. Bacteriophage T4 anticodon nuclease, polynucleotide kinase and RNA ligase reprocess the host lysine tRNA. *EMBO J.* 6(8):2499–503
54. David M, Borasio GD, Kaufmann G. 1982. T4 bacteriophage-coded polynucleotide kinase and RNA ligase are involved in host tRNA alteration and repair. *Virology* 123(2):480–83

55. Unterholzner SJ, Poppenberger B, Rozhon W. 2013. Toxin-antitoxin systems: biology, identification, and application. *Mob. Genet. Elements* 3(5):e26219
56. Leplae R, Geeraerts D, Hallez R, Guglielmini J, Drèze P, Van Melderen L. 2011. Diversity of bacterial type II toxin-antitoxin systems: a comprehensive search and functional analysis of novel families. *Nucleic Acids Res.* 39(13):5513–25
57. Schuster CF, Bertram R. 2013. Toxin-antitoxin systems are ubiquitous and versatile modulators of prokaryotic cell fate. *FEMS Microbiol. Lett.* 340(2):73–85
58. Ramage HR, Connolly LE, Cox JS. 2009. Comprehensive functional analysis of *Mycobacterium tuberculosis* toxin-antitoxin systems: implications for pathogenesis, stress responses, and evolution. *PLoS Genet.* 5(12):e1000767
59. Christensen SK, Mikkelsen M, Pedersen K, Gerdes K. 2001. RelE, a global inhibitor of translation, is activated during nutritional stress. *PNAS* 98(25):14328–33
60. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. 2004. Specialized persister cells and the mechanism of multidrug tolerance in *Escherichia coli*. *J. Bacteriol.* 186(24):8172–80
61. Wang X, Wood TK. 2011. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response. *Appl. Environ. Microbiol.* 77(16):5577–83
62. Gerdes K, Rasmussen PB, Molin S. 1986. Unique type of plasmid maintenance function: postsegregational killing of plasmid-free cells. *PNAS* 83(10):3116–20
63. Song S, Wood TK. 2018. Post-segregational killing and phage inhibition are not mediated by cell death through toxin/antitoxin systems. *Front. Microbiol.* 9:814
64. Svenson SB, Karlström OH. 1976. Bacteriophage T4-induced shut-off of host-specific translation. *J. Virol.* 17(2):326–34
65. Kai T, Selick HE, Yonesaki T. 1996. Destabilization of bacteriophage T4 mRNAs by a mutation of gene 61.5. *Genetics* 144(1):7–14
66. Emond E, Dion E, Walker SA, Vedamuthu ER, Kondo JK, Moineau S. 1998. AbiQ, an abortive infection mechanism from *Lactococcus lactis*. *Appl. Environ. Microbiol.* 64(12):4748–56
67. Blower TR, Pei XY, Short FL, Fineran PC, Humphreys DP, et al. 2011. A processed noncoding RNA regulates an altruistic bacterial antiviral system. *Nat. Struct. Mol. Biol.* 18(2):185–90
68. Blower TR, Evans TJ, Przybilski R, Fineran PC, Salmond GPC. 2012. Viral evasion of a bacterial suicide system by RNA-based molecular mimicry enables infectious altruism. *PLoS Genet.* 8(10):e1003023
69. Davies BW, Bogard RW, Young TS, Mekalanos JJ. 2012. Coordinated regulation of accessory genetic elements produces cyclic di-nucleotides for *V. cholerae* virulence. *Cell* 149(2):358–70
70. Severin GB, Ramliden MS, Hawver LA, Wang K, Pell ME, et al. 2018. Direct activation of a phospholipase by cyclic GMP-AMP in El Tor *Vibrio cholerae*. *PNAS* 115(26):E6048–55
71. Whiteley AT, Eaglesham JB, de Oliveira Mann CC, Morehouse BR, Lowey B, et al. 2019. Bacterial cGAS-like enzymes synthesize diverse nucleotide signals. *Nature* 567(7747):194–99
72. Ye Q, Lau RK, Mathews IT, Birkholz EA, Watrous JD, et al. 2020. HORMA domain proteins and a Trip13-like ATPase regulate bacterial cGAS-like enzymes to mediate bacteriophage immunity. *Mol. Cell* 77(4):709–22
73. Burroughs AM, Zhang D, Schäffer DE, Iyer LM, Aravind L. 2015. Comparative genomic analyses reveal a vast, novel network of nucleotide-centric systems in biological conflicts, immunity and signaling. *Nucleic Acids Res.* 43(22):10633–54
74. Sorek R, Lawrence CM, Wiedenheft B. 2013. CRISPR-mediated adaptive immune systems in bacteria and archaea. *Annu. Rev. Biochem.* 82:237–66
75. Terns MP, Terns RM. 2011. CRISPR-based adaptive immune systems. *Curr. Opin. Microbiol.* 14(3):321–27
76. Marraffini LA. 2015. CRISPR-Cas immunity in prokaryotes. *Nature* 526(7571):55–61
77. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, et al. 2015. An updated evolutionary classification of CRISPR-Cas systems. *Nat. Rev. Microbiol.* 13(11):722–36
78. Tamulaitis G, Venclovas Č, Siksnys V. 2017. Type III CRISPR-Cas immunity: major differences brushed aside. *Trends Microbiol.* 25(1):49–61
79. Kazlauskienė M, Tamulaitis G, Kostiuk G, Venclovas Č, Siksnys V. 2016. Spatiotemporal control of type III-A CRISPR-Cas immunity: coupling DNA degradation with the target RNA recognition. *Mol. Cell* 62(2):295–306

80. Liu TY, Iavarone AT, Doudna JA. 2017. RNA and DNA targeting by a reconstituted *Thermus thermophilus* type III-A CRISPR-Cas system. *PLOS ONE* 12(1):e0170552
81. Amitai G, Sorek R. 2017. Intracellular signaling in CRISPR-Cas defense. *Science* 357(6351):550–51
82. Athukoralage JS, McMahon S, Zhang C, Grüşchow S, Graham S, et al. 2020. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity. *Nature* 577:572–75
83. Athukoralage JS, Graham S, Grüşchow S, Rouillon C, White MF. 2019. A type III CRISPR ancillary ribonuclease degrades its cyclic oligoadenylate activator. *J. Mol. Biol.* 431(15):2894–99
84. Meeske AJ, Nakandakari-Higa S, Marraffini LA. 2019. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage. *Nature* 570(7760):241–45
85. Mendoza SD, Bondy-Denomy J. 2019. Cas13 helps bacteria play dead when the enemy strikes. *Cell Host Microbe* 26(1):1–2
86. Labrie S, Samson J, Moineau S. 2010. Bacteriophage resistance mechanisms. *Nat. Rev. Microbiol.* 8:317–27
87. Dedrick RM, Jacobs-Sera D, Guerrero Bustamante CA, Garlena RA, Mavrich TN. 2017. Prophage-mediated defense against viral attack and viral counter-defense. *Nat. Microbiol.* 2:16251
88. Gentile GM, Wetzel KS, Dedrick RM, Montgomery MT, Garlena RA, et al. 2019. More evidence of collusion: a new prophage-mediated viral defense system encoded by mycobacteriophage Sbash. *mBio* 10:e00196-19
89. Montgomery MT, Guerrero Bustamante CA, Dedrick RM, Jacobs-Sera D, Hatfull GF. 2019. Yet more evidence of collusion: a new viral defense system encoded by *Gordonia* phage CarolAnn. *mBio* 10:e02417-18



Contents

History

- A Rewarding Career Unraveling the Pathogenesis of Viral Infections
Diane E. Griffin 1
- Investigating Viruses During the Transformation of Molecular
Biology: Part II
Bernard Moss 15

Ecology and Evolution

- Actinobacteriophages: Genomics, Dynamics, and Applications
Graham F. Hatfull 37
- Within-Host Viral Diversity: A Window into Viral Evolution
Adam S. Lauring 63
- Seasonality of Respiratory Viral Infections
Miyu Moriyama, Walter J. Hugentobler, and Akiko Iwasaki 83
- The Potential Role of Endogenous Viral Elements in the Evolution
of Bats as Reservoirs for Zoonotic Viruses
*Emilia C. Skirmuntt, Marina Escalera-Zamudio, Emma C. Teeling,
Adrian Smith, and Aris Katzourakis* 103
- Ecology, Structure, and Evolution of *Shigella* Phages
Sundharraman Subramanian, Kristin N. Parent, and Sarah M. Doore 121

Attachment and Cell Entry

- Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans
*Melanie Koehler, Martin Delguste, Christian Sieben, Laurent Gillet,
and David Alsteens* 143

Genome Replication, Regulation of Gene Expression, and Biosynthesis

- Post-Translation Regulation of Influenza Virus Replication
Anthony R. Dawson, Gary M. Wilson, Joshua J. Coon, and Andrew Meble 167

RNA Lariat Debranching Enzyme as a Retroviral and Long-Terminal-Repeat Retrotransposon Host Factor <i>Thomas M. Menees</i>	189
The Curious Strategy of Multipartite Viruses <i>Yannis Michalakis and Stéphane Blanc</i>	203
Regulators of Viral Frameshifting: More Than RNA Influences Translation Events <i>Wesley D. Penn, Haley R. Harrington, Jonathan P. Schleich, and Suchetana Mukhopadhyay</i>	219
Virus Cell Biology	
Cellular Electron Cryo-Tomography to Study Virus-Host Interactions <i>Emmanuelle R.J. Queminn, Emily A. Machala, Benjamin Vollmer, Vojtěch Pražák, Daven Vasishtan, Rene Rosch, Michael Grange, Linda E. Franken, Lindsay A. Baker, and Kay Grünewald</i>	239
The Hepatitis B Virus Envelope Proteins: Molecular Gymnastics Throughout the Viral Life Cycle <i>Stefan Seitz, Jelena Habjanič, Anne K. Schütz, and Ralf Bartenschlager</i>	263
Transformation and Oncogenesis	
Molecular Mechanisms of Merkel Cell Polyomavirus Transformation and Replication <i>Wei Liu and Jianxin You</i>	289
Herpesvirus Epigenetic Reprogramming and Oncogenesis <i>Yonggang Pei, Josiah Hiu-yuen Wong, and Erle S. Robertson</i>	309
Pathogenesis	
Single-Cell Analysis Reveals Heterogeneity of Virus Infection, Pathogenicity, and Host Responses: HIV as a Pioneering Example <i>Ludivine Brandt, Sara Cristinelli, and Angela Ciuffi</i>	333
Viral Hacks of the Plant Vasculature: The Role of Phloem Alterations in Systemic Virus Infection <i>Madhu Kappagantu, Tamara D. Collum, Christopher Dardick, and James N. Culver</i>	351
Abortive Infection: Bacterial Suicide as an Antiviral Immune Strategy <i>Anna Lopatina, Nitzan Tal, and Rotem Sorek</i>	371
Mucosal Dendritic Cell Subsets Control HIV-1's Viral Fitness <i>Bernadien M. Nijmeijer, Catharina J.M. Langedijk, and Teunis B.H. Geijtenbeek</i>	385

Autophagy in Plant-Virus Interactions <i>Meng Yang, Asigul Ismayil, and Yule Liu</i>	403
---	-----

Immunity

Viperin Reveals Its True Function <i>Efraín E. Rivera-Serrano, Anthony S. Gizzi, Jamie J. Arnold, Tyler L. Grove, Steven C. Almo, and Craig E. Cameron</i>	421
---	-----

Vaccines

Vaccines to Emerging Viruses: Nipah and Hendra <i>Moushimi Amaya and Christopher C. Broder</i>	447
Ethics of Conducting Clinical Research in an Outbreak Setting <i>Kathryn M. Edwards and Sonali Kochhar</i>	475
Challenges of Making Effective Influenza Vaccines <i>Sigrid Gouma, Elizabeth M. Anderson, and Scott E. Hensley</i>	495

Viral Vectors and Therapeutics

Plant Virus-Derived Vectors: Applications in Agricultural and Medical Biotechnology <i>Peter Abrahamian, Rosemarie W. Hammond, and John Hammond</i>	513
A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies <i>Anna Hartley, Gayatri Kavishwar, Ilaria Salvato, and Antonio Marchini</i>	537
Plant Viruses and Bacteriophage-Based Reagents for Diagnosis and Therapy <i>Sourabh Shukla, He Hu, Hui Cai, Soo-Khim Chan, Christine E. Boone, Veronique Beiss, Paul L. Chariou, and Nicole F. Steinmetz</i>	559

Errata

An online log of corrections to *Annual Review of Virology* articles may be found at
<http://www.annualreviews.org/errata/virology>